Folic acid conjugated nanoliposomes as promising carriers for targeted delivery of bleomycin

References

• Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40:362–382.
   PubMed Web of Science ®Google Scholar
• Oken MM, Crooke ST, Elson MK, et al. Pharmacokinetics of bleomycin after i.m. administration in man. Cancer Treat Rep. 1981;65:485–489.
   PubMedGoogle Scholar
• Tozon N, Kodre V, Sersa G, et al. Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res. 2005;25:839–845.
   PubMed Web of Science ®Google Scholar
• Koshkaryev A, Piroyan A, Torchilin VP. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett. 2013;334:293–301.
   PubMed Web of Science ®Google Scholar
• Gwinn WM, Kapita MC, Wang PM, et al. Synthetic liposomes are protective from bleomycin-induced lung toxicity. Am J Physiol Lung Cell Mol Physiol. 2011;301:L207–L217.
   PubMed Web of Science ®Google Scholar
• Chiani M, Shokrgoar MA, Azadmanesh K, et al. Preparation, characterization, and in vitro evaluation of bleomycin-containing nanoliposomes. Chem Biol Drug Des. 2017;89:492–497.
   PubMed Web of Science ®Google Scholar
• Sludden J, Uchegbu IF, Schätzlein AG. The encapsulation of bleomycin within chitosan based polymeric vesicles does not alter its biodistribution. J Pharm Pharmacol. 2000;52:377–382.
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Edelman MJ, Bever SL, et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol. 2012;30:4011–4016.
   PubMed Web of Science ®Google Scholar
• Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007;7:6.
   PubMedGoogle Scholar
• Shi H, Guo J, Li C, et al. A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Dev Ther. 2015;9:4989–4996.
   PubMed Web of Science ®Google Scholar
• Marchetti C, Palaia I, Giorgini M, et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther. 2014;7:1223–1236.
   PubMed Web of Science ®Google Scholar
• Mansoori GA, Brandenburg KS, Shakeri-Zadeh A. A comparative study of two folate-conjugated gold nanoparticles for cancer nanotechnology applications. Cancers (Basel). 2010;2:1911–1928.
   PubMedGoogle Scholar
• Chen H, Ahn R, Van den Bossche J, et al. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther. 2009;8:1955–1963.
   PubMed Web of Science ®Google Scholar
• Shmeeda H, Mak L, Tzemach D, et al. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther. 2006;5:818–824.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhou J, Ying X, et al. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. JPPS. 2010;13:136–151.
   Google Scholar
• Hogset A, Prasmickaite L, Tjelle TE, et al. Photochemical transfection: a new technology for light-induced, site-directed gene delivery. Hum Gene Ther. 2000;11:869–880.
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release. 2007;120:169–177.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, White AJ, Weil SC, et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013;129:452–458.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:3–19.
   PubMed Web of Science ®Google Scholar
• Firth GB, Firth M, McKeran RO, et al. Application of radioimmunoassay to monitor treatment of human cerebral gliomas with bleomycin entrapped within liposomes. J Clin Pathol. 1988;41:38–43.
   PubMed Web of Science ®Google Scholar
• Sriraman SK, Pan J, Sarisozen C, et al. Enhanced cytotoxicity of folic acid-targeted liposomes co-loaded with C6 ceramide and doxorubicin: in vitro evaluation on HeLa, A2780-ADR, and H69-AR cells. Mol Pharm. 2016;13:428–437.
   PubMed Web of Science ®Google Scholar
• Wu D, Zheng Y, Hu X, et al. Anti-tumor activity of folate targeted biodegradable polymer–paclitaxel conjugate micelles on EMT-6 breast cancer model. Mater Sci Eng C Mater Biol Appl. 2015;53:68–75.
   PubMed Web of Science ®Google Scholar
• Kayat J, Mehra NK, Gajbhiye V, et al. Drug targeting to arthritic region via folic acid appended surface-engineered multi-walled carbon nanotubes. J Drug Target. 2016;24:318–327.
   PubMed Web of Science ®Google Scholar
• Alomrani AH, El Maghraby GM, Alanazi FK, et al. Liposomes for enhanced cytotoxic activity of bleomycin. Drug Dev Res. 2011;72:265–273.
   Web of Science ®Google Scholar